Skip to navigation Skip to content

T-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051112

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised brentuximab vedotin, mogamulizumab and vorinostat for patients with cutaneous T-cell lymphoma (CTCL), and brentuximab vedotin for patients with peripheral T-cell lymphoma (PTCL).

For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.

T-cell lymphoma quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber Self-serve

Initial (CTCL)

PB216 form

Written

Electronic

S85:

vorinostat

S100:

mogamulizumab

No

OPA

Yes

Initial (CTCL)

PB268 form

Written

Electronic

S100:

brentuximab vedotin

No

OPA

Yes

Initial (PTCL)

PB314 form

Written

Electronic

S100:

brentuximab vedotin

No

OPA

Yes

Continuing

Telephone

Electronic

S85:

vorinostat

S100:

brentuximab vedotin

mogamulizumab

No

OPA

Yes